| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441213 | European Journal of Cancer | 2016 | 8 Pages |
Abstract
Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. According to the selection design, differences in the superiority between these maintenance therapies were not demonstrated.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Masato Karayama, Naoki Inui, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Shigeki Kuroishi, Koshi Yokomura, Naoki Koshimizu, Masaki Sato, Mikio Toyoshima, Toshihiro Shirai, Masafumi Masuda, Takashi Yamada, Shiro Imokawa, Takafumi Suda,